Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Sand, Kristoffer Evebø ^a   Rye, Kristin Paulsen ^a   Mannsåker, Bård ^a   Bruserud, Øystein ^a,b   Kittang, Astrid Olsnes ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemokines; Myelodysplastic syndrome; T cells

Indexed keywords

CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CX3CR1;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

EID: 84886944438     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23138     Document Type: Article

References (35)

1. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392:565-8; PMID:9560152; http://dx.doi.org/10.1038/33340.
2. Moser B. T-cell memory: the importance of chemokinemediated cell attraction. Curr Biol 2006; 16:R504-7; PMID:16824912; http://dx.doi.org/10.1016/j.cub.2006.06.008.
3. Moser B, Willimann K. Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis 2004; 63(Suppl 2):ii84-9; PMID:15479880; http://dx.doi.org/10.1136/ard.2004.028316.
4. Laurence AD. Location, movement and survival: the role of chemokines in haematopoiesis and malignancy. Br J Haematol 2006; 132:255-67; PMID:16409290; http://dx.doi.org/10.1111/j.1365-2141.2005.05841.x.
5. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 2006; 25:357-71; PMID:17016763; http://dx.doi.org/10.1007/s10555-006-9003-5.
6. Müller G, Höpken UE, Stein H, Lipp M. Systemic immunoregulatory and pathogenic functions of homeostatic chemokine receptors. J Leukoc Biol 2002; 72:1-8; PMID:12101256.
7. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007; 25:787-820; PMID:17291188; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090529.
8. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004; 25:75-84; PMID:15102366; http://dx.doi.org/10.1016/j.it.2003.12.005.
9. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998; 83:358-68; PMID:9592987.
10. Swerdlow SCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, et al. WHO Classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC; 2008.
11. Cazzola M, Malcovati L. Myelodysplastic syndromes- -coping with ineffective hematopoiesis. N Engl J Med 2005; 352:536-8; PMID:15703418; http://dx.doi.org/10.1056/NEJMp048266.
12. Epling-Burnette PK, Painter JS, Rollison DE, Ku E, Vendron D, Widen R, et al. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia 2007; 21:659-67; PMID:17301813.1. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392:565-8; PMID:9560152; http://dx.doi.org/10.1038/33340.
13. Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996; 33:150-62; PMID:8722685.
14. Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM, Bontkes HJ. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 2011; 153:568-81; PMID:21488861; http://dx.doi.org/10.1111/j.1365-2141.2011.08683.x.
15. Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010; 116:4251-61; PMID:20679526; http://dx.doi.org/10.1182/blood-2010-01-262071.
16. Pardanani A, Finke C, Lasho TL, Al-Kali A, Begna KH, Hanson CA, et al. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia 2012; 26:693-9; PMID:21912394; http://dx.doi.org/10.1038/leu.2011.251.
17. Comerford I, Bunting M, Fenix K, Haylock-Jacobs S, Litchfield W, Harata-Lee Y, et al. An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation?: CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. Bioessays 2010; 32:1067-76; PMID:20954179; http://dx.doi.org/10.1002/bies.201000063.
18. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003; 14:409-26; PMID:12948524; http://dx.doi.org/10.1016/S1359-6101(03)00049-2.
19. Zhang Y, Zhao H, Zhao D, Sun L, Zhi Y, Wu X, et al. SDF-1/CXCR4 axis in myelodysplastic syndromes: correlation with angiogenesis and apoptosis. Leuk Res 2012; 36:281-6; PMID:21802140; http://dx.doi.org/10.1016/j.leukres.2011.06.017.
20. Yang R, Pu J, Guo J, Xu F, Zhang Z, Zhao Y, et al. The biological behavior of SDF-1/CXCR4 in patients with myelodysplastic syndrome. Med Oncol 2012; 29:1202-8; PMID:21556934; http://dx.doi.org/10.1007/s12032-011-9943-7.
21. Matsuda M, Morita Y, Hanamoto H, Tatsumi Y, Maeda Y, Kanamaru A. CD34+ progenitors from MDS patients are unresponsive to SDF-1, despite high levels of SDF-1 in bone marrow plasma. Leukemia 2004; 18:1038-40; PMID:14762446; http://dx.doi.org/10.1038/sj.leu.2403301.
22. Kotsianidis I, Bouchliou I, Nakou E, Spanoudakis E, Margaritis D, Christophoridou AV, et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009; 23:510-8; PMID:19020538; http://dx.doi.org/10.1038/leu.2008.333.
23. Akkök CA, Liseth K, Hervig T, Ryningen A, Bruserud O, Ersvaer E. Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators. Cytotherapy 2009; 11:749-60; PMID:19878061; http://dx.doi.org/10.3109/14653240902980443.
24. Sparrow RL, Komodromou H, Tippett E, Georgakopoulos T, Xu W. Apoptotic lymphocytes and CD34+ cells in cryopreserved cord blood detected by the fluorescent vital dye SYTO 16 and correlation with loss of L-selectin (CD62L) expression. Bone Marrow Transplant 2006; 38:61-7; PMID:16788684; http://dx.doi.org/10.1038/sj.bmt.1705405.
25. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003; 4:835-42; PMID:12942084; http://dx.doi.org/10.1038/ni969.
26. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22:745-63; PMID:15032595; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104702.
27. Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM, Pfannes LV, et al. Altered naive and memory CD4+T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia 2009; 23:1288-96; PMID:19282834; http://dx.doi.org/10.1038/leu.2009.14.
28. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12; PMID:10537110; http://dx.doi.org/10.1038/44385.
29. Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M, et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002; 168:6173-80; PMID:12055230.
30. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001; 29:1270-7; PMID:11698122; http://dx.doi.org/10.1016/S0301-472X(01)00736-6.
31. Kordasti SY, Afzali B, Lim Z, Ingram W, Hayden J, Barber L, et al. IL-17-producing CD4(+) T cells, proinflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009; 145:64-72; PMID:19210506; http://dx.doi.org/10.1111/j.1365-2141.2009.07593.x.
32. Bruserud O, Ryningen A, Olsnes AM, Stordrange L, Øyan AM, Kalland KH, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007; 92:332-41; PMID:17339182; http://dx.doi.org/10.3324/haematol.10148.
33. Olsnes AM, Ryningen A, Ersvaer E, Bruserud O. Invitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22. J Interferon Cytokine Res 2008; 28:297-310; PMID:18547160; http://dx.doi.org/10.1089/jir.2007.0052.
34. Kobayashi N, Takata H, Yokota S, Takiguchi M. Down-regulation of CXCR4 expression on human CD8+ T cells during peripheral differentiation. Eur J Immunol 2004; 34:3370-8; PMID:15549771; http://dx.doi.org/10.1002/eji.200425587.
35. Berhanu D, Mortari F, De Rosa SC, Roederer M. Optimized lymphocyte isolation methods for analysis of chemokine receptor expression. J Immunol Methods 2003; 279:199-207; PMID:12969561; http://dx.doi.org/10.1016/S0022-1759(03)00186-8.